Glycated albumin (Amadori product) induces activation of MAP kinases in monocyte-like MonoMac 6 cells.
Increased levels of glycated, Amadori-modified albumin are a risk factor for diabetic vascular disorders. Glycated albumin binds to specific receptors and induces cellular signaling pathways, the complexity of which is largely unknown. Binding of glycated albumin to MonoMac 6 cells leads to an activation of MAPK p44/42 (ERK1/2) and p38 with subsequent translocation of NF-kappaB into the nucleus. The activation of MAPK is in part mediated by protein kinase C activation, but a PKC-independent pathway via MEK-1 is also involved. Protein tyrosine kinases do not play a role in the activation of NF-kappaB. The results may have pathophysiological significance, because the MonoMac 6 cell line is not greatly different from blood monocytes.
Brandt
Rowena
R
Institute of Medical Biochemistry and Molecular Biology, Ernst Moritz Arndt University, Klinikum Sauerbruchstrasse, D-17487 Greifswald, Germany. rowena.brandt@uni-greifswald.de
Krantz
Sven
S
D002478:Cells, Cultured; D017127:Glycation End Products, Advanced; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D009000:Monocytes / Q000201:enzymology* / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D011493:Protein Kinase C / Q000378:metabolism; D012709:Serum Albumin / Q000494:pharmacology*; D015398:Signal Transduction; D000093423:Glycated Serum Albumin
D017127:Glycation End Products, Advanced; D016328:NF-kappa B; D012709:Serum Albumin; D011493:Protein Kinase C; D020928:Mitogen-Activated Protein Kinases; D000093423:Glycated Serum Albumin